President Trump is considering removing three Federal Reserve Board members—Jerome Powell, Lisa Cook, and Michael Barr—following a watchdog report on costly renovations at the Fed's headquarters. The report found management issues but no criminal wrongdoing, limiting grounds for removal. Legal hurdles and ongoing litigation, including a Supreme Court ruling protecting Cook, could delay or complicate any removals. While Trump criticizes Powell and others, these moves may backfire by keeping the governors in place and not affecting Fed interest rate decisions before the upcoming midterm elections.
The story about President Trump potentially targeting three Federal Reserve governors is presented here with a snapshot of the Financials sector on Pluang as of Oct 02, 2026 01:21 WIB. Among 85 priced US Financials stocks, 35 rose and 50 fell. Notably, NU (Nu Holdings Ltd) gained 3.67% with 90% buy orders and a typical hold time of 53 days, contrasting with BCS (Barclays PLC) which dropped 3.63% despite 93% buy orders and a longer hold time of 62 days, while RIOT (Riot Platforms Inc) fell 3.28% with a shorter hold time of 16 days and 77% buy orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
